Intravitreal Injectable Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Intravitreal Injectable market size was valued at USD 14950 million in 2022 and is forecast to a readjusted size of USD 23690 million by 2029 with a CAGR of 6.8% during review period.

Intravitreal Injectable are shot of medicine into the eye. It was first used to administer drugs to treat endophthalmitis and cytomegalovirus retinitis. Recently, it is used to treat age-related macular degeneration and many other retinal diseases as well.

Global Intravitreal Injectable key players include Regeneron Pharmaceuticals (Eylea), Allergan, EyePoint Pharmaceuticals, Genentech, Kanghong Pharmaceutical, etc. Global top five manufacturers hold a share over 70%. North Amercia is the largest market, with a share over 50%, followed by Europe and Asia-Pacific, both have a share over 40 percent.In terms of drug, Anti-VEGF is the largest segment, with a share over 85%. And in terms of disease, the largest application is Macular Edema, followed by Macular Degeneration, Retinal Vein Occlusion, etc.

This report is a detailed and comprehensive analysis for global Intravitreal Injectable market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Drug and by Disease. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Intravitreal Injectable market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Intravitreal Injectable market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Intravitreal Injectable market size and forecasts, by Drug and by Disease, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Intravitreal Injectable market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Intravitreal Injectable
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Intravitreal Injectable market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Regeneron Pharmaceuticals (Eylea)
   Allergan
   EyePoint Pharmaceuticals
   Genentech
   Kanghong Pharmaceutical

   Anti-VEGF
   Steroids
   Others

   Macular Degeneration
   Macular Edema
   Uveitis
   Retinal Vein Occlusion
   Others

   North America (United States, Canada and Mexico)
   Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
   South America (Brazil, Argentina, Colombia, and Rest of South America)
   Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

What are the strengths of the Intravitreal Injectable Market in 2025?

The strengths include increasing adoption of injectable therapies for retinal diseases, significant advancements in drug formulations, and the growing prevalence of conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. Additionally, intravitreal injectables offer precise drug delivery, improving treatment outcomes and patient compliance.

What are the weaknesses of this market?

The major weaknesses include the high cost of treatment, which can limit accessibility, as well as the potential for side effects like eye infections or inflammation. Additionally, the complexity of the injection procedure may deter some patients, and the need for regular injections can be burdensome.

What are the opportunities in the Intravitreal Injectable Market?

Opportunities lie in the continued innovation of new drug formulations, especially long-acting injectables that reduce treatment frequency. There is also significant growth potential in emerging markets, as increasing healthcare access and awareness drive demand. Furthermore, combining injectables with gene therapies or cell-based treatments could provide novel therapeutic options.

What are the threats to this market?

Threats include the potential for market saturation, as competition increases with the introduction of generics and biosimilars. Regulatory hurdles and potential safety concerns about long-term use of intravitreal injections also pose risks. Additionally, alternative treatment methods such as laser therapies or surgical interventions may challenge the dominance of injectables.

What are the political factors affecting the Intravitreal Injectable Market in 2025?

Political factors include government regulations surrounding drug approvals, reimbursement policies, and healthcare funding. Variability in healthcare policies across regions could impact the accessibility and affordability of intravitreal injectables, particularly in emerging markets. Additionally, political instability in certain regions could disrupt supply chains.

How do economic factors impact this market?

Economic factors such as healthcare expenditure, disposable income levels, and reimbursement rates play a significant role. In high-income countries, the demand for advanced treatments may increase, while in low-income countries, the cost of intravitreal injectables may limit accessibility. The overall economic climate can affect both patient spending and government healthcare budgets.

What are the social factors influencing the market?

Social factors include the aging population, which is more prone to retinal diseases like AMD and diabetic retinopathy. Increasing awareness of eye health and advancements in patient education can drive demand for these treatments. However, patient acceptance and willingness to undergo frequent injections may also impact market growth.

How do technological factors shape the Intravitreal Injectable Market?

Technological advancements in drug delivery systems, such as longer-acting injectables and improved needle technology, are shaping the market. The development of combination therapies and new drug formulations offers opportunities for better treatment outcomes. Additionally, innovations in diagnostic tools and personalized medicine are contributing to more tailored and effective treatments.

What environmental factors should be considered?

Environmental factors mainly concern the sustainability of production processes and the environmental impact of medical waste. The industry must adhere to eco-friendly practices in drug packaging and disposal. Furthermore, climate change and natural disasters could disrupt manufacturing and distribution channels, impacting market supply.

How do legal factors affect this market?

Legal factors include intellectual property rights, patent expirations, and regulatory frameworks for approval and market entry. The presence of generics and biosimilars due to expiring patents poses both challenges and opportunities. Furthermore, legal guidelines for clinical trials and patient safety standards must be adhered to, ensuring drug safety and efficacy.

Who are the suppliers in the Intravitreal Injectable Market 2025?

Suppliers include pharmaceutical companies producing injectables, raw material suppliers for drug formulation, and manufacturers of injection devices (such as syringes and needles). Additionally, suppliers of packaging materials and distributors play key roles in ensuring the availability of intravitreal injectables.

What are the inputs in the Intravitreal Injectable Market?

The inputs include raw materials for drug production, manufacturing facilities, skilled labor, research and development resources, and clinical trial data. Additionally, regulatory approvals, marketing strategies, and distribution channels are essential inputs that contribute to the market.

What are the processes involved in the Intravitreal Injectable Market?

Processes include drug research and development, clinical trials, regulatory approval, manufacturing of injectables, quality control, packaging, distribution, and marketing. Post-market surveillance and ongoing patient support services also contribute to the overall process flow.

Who are the customers in the Intravitreal Injectable Market?

Customers include healthcare providers such as hospitals, ophthalmologists, and clinics, as well as patients suffering from retinal diseases like age-related macular degeneration (AMD) or diabetic retinopathy. Pharmaceutical distributors and healthcare insurers are also key stakeholders in the customer chain.

What are the outputs of the Intravitreal Injectable Market?

The outputs include the intravitreal injectables themselves, which are delivered to healthcare providers and patients. Additionally, market outputs include patient outcomes, such as improved vision and disease management, as well as market growth data, sales reports, and new drug approvals in the sector.

How strong is the threat of new entrants in the Intravitreal Injectable Market 2025?

The threat of new entrants is moderate. While the market offers lucrative opportunities, high barriers to entry exist due to stringent regulatory requirements, the need for substantial R&D investment, and established competition from major pharmaceutical companies. Additionally, the complex manufacturing processes and high cost of drug development limit new competitors.

How intense is the bargaining power of suppliers in this market?

The bargaining power of suppliers is relatively low to moderate. Although suppliers of raw materials and specialized devices (such as syringes and needles) are important, the market is large and diverse enough that there are multiple sources of supply. However, limited suppliers for certain high-quality active ingredients or novel drug delivery systems could increase their bargaining power.

How strong is the bargaining power of buyers in the Intravitreal Injectable Market?

The bargaining power of buyers is moderate. Large healthcare institutions, insurance providers, and government agencies may have some leverage due to volume purchasing and negotiated pricing. However, individual patients and smaller clinics typically have less bargaining power, as the treatments are often specialized and costly, with limited alternatives.

What is the threat of substitute products or services in the Intravitreal Injectable Market?

The threat of substitutes is moderate to low. While alternative treatments such as laser therapies, oral medications, and surgical options exist, they are often less effective or carry higher risks compared to intravitreal injectables. The specificity of injectable treatments for certain retinal diseases further limits the threat of substitutes in this market.

How intense is the rivalry among existing competitors in the Intravitreal Injectable Market?

The rivalry among existing competitors is high. The market is dominated by several large pharmaceutical companies, each vying for market share with similar products. Competition is further heightened by the potential for biosimilars and generics entering the market as patents for key drugs expire. This drives constant innovation, pricing strategies, and marketing efforts to maintain leadership.

What are the key raw materials required in the Intravitreal Injectable Market?

The key raw materials include active pharmaceutical ingredients (APIs), which are the drugs used in the injectables, as well as excipients for drug stabilization. Packaging materials such as vials, syringes, and needles are also essential. Additionally, specialized components for drug delivery systems, such as biologic-based substances or formulations for longer-acting injectables, are crucial.

What are the main suppliers in the upstream value chain for this market?

The main suppliers include manufacturers of raw materials like chemical and biotech companies that produce APIs and excipients. Device manufacturers supplying syringes, needles, and other injection components also play a critical role. Additionally, specialized suppliers providing technologies for drug formulation and delivery systems are vital to the upstream process.

How do regulatory requirements affect the upstream value chain in the Intravitreal Injectable Market?

Regulatory requirements significantly influence the upstream value chain. Manufacturers must comply with strict regulatory standards for drug development, including clinical trials, safety testing, and good manufacturing practices (GMP). The approval process by regulatory agencies such as the FDA or EMA ensures that only safe and effective products enter the market, which can delay production and increase costs for upstream suppliers.

What role does research and development (R&D) play in the upstream market?

R&D plays a critical role in the upstream market by driving the discovery of new formulations, drug delivery technologies, and innovative injectable devices. R&D is essential for creating long-acting intravitreal injectables, improving patient compliance, and enhancing therapeutic outcomes. Investment in R&D directly impacts the availability and competitiveness of new products in the market.

How does the cost of raw materials affect the upstream value chain?

The cost of raw materials directly impacts the upstream value chain, as fluctuations in the prices of APIs, excipients, and packaging materials can influence production costs. Higher costs for biologics or specialized materials could lead to increased prices for end products, which might affect overall market accessibility. Efficient supply chain management and cost-control strategies are necessary to maintain profitability.

What are the key challenges faced by upstream suppliers in this market?

Key challenges include meeting the stringent regulatory standards and ensuring the consistency and quality of materials, particularly for biologics or specialized injectables. Supply chain disruptions, such as those caused by raw material shortages or geopolitical issues, can also affect production. Additionally, rising costs for research, development, and compliance create financial pressures for upstream suppliers.

What are the key players in the midstream value chain for the Intravitreal Injectable Market?

The key players in the midstream value chain are the pharmaceutical manufacturers who are responsible for the production, formulation, and packaging of intravitreal injectables. These companies handle the scale-up processes from R&D to commercialization. Additionally, contract manufacturing organizations (CMOs) and distribution partners play significant roles in ensuring efficient production and delivery to healthcare providers.

How does manufacturing impact the midstream value chain?

Manufacturing is central to the midstream value chain, as it converts raw materials into market-ready intravitreal injectables. Efficient and high-quality manufacturing processes are critical for ensuring product safety, regulatory compliance, and timely delivery. The ability to scale production while maintaining consistent product quality is a key challenge for midstream players.

What role do distribution channels play in the midstream market?

Distribution channels are essential in ensuring the availability of intravitreal injectables in hospitals, clinics, and pharmacies. Efficient distribution networks ensure timely delivery, minimize stockouts, and manage the cold chain requirements for biologics. Partnerships with wholesalers, specialty pharmacies, and direct-to-provider channels are crucial for maximizing reach in the midstream value chain.

What are the key challenges faced by midstream players in this market?

Midstream players face challenges such as regulatory compliance with ever-evolving standards for injectable medications. The cold chain logistics required for certain biologic injectables add complexity to distribution. Additionally, there is constant pressure to maintain cost efficiency while addressing supply chain disruptions and ensuring the availability of products in a competitive market.

How do market dynamics impact the midstream segment?

Market dynamics such as pricing pressures, the introduction of generics, and the growing preference for long-acting formulations influence the midstream segment. The increasing demand for specialized treatments and personalized care requires midstream players to adapt quickly, ensuring they can handle a diverse range of products while maintaining cost-effectiveness. Midstream companies also need to keep pace with technological advancements in drug delivery and patient management.

What are the key players in the downstream value chain for the Intravitreal Injectable Market?

The key players in the downstream value chain are healthcare providers such as ophthalmologists, retina specialists, and hospitals, who directly administer intravitreal injectables to patients. Additionally, insurance companies, healthcare payers, and patients are integral components, with insurance providing coverage and patients receiving the treatments.

How do healthcare providers impact the downstream market?

Healthcare providers are crucial in the downstream market as they prescribe and administer intravitreal injectables. Their experience, trust in the drug, and patient management capabilities significantly influence the adoption and continued use of these treatments. Providers also play a key role in educating patients about treatment regimens and potential side effects.

What role does patient acceptance play in the downstream market?

Patient acceptance is vital to the success of the downstream market. As intravitreal injections require repeated visits, patient compliance and comfort with the procedure directly affect treatment outcomes. Factors such as affordability, accessibility, and the perceived effectiveness of the therapy influence patient willingness to undergo frequent injections.

How do reimbursement policies affect the downstream value chain?

Reimbursement policies play a significant role in shaping the downstream value chain by determining the accessibility and affordability of intravitreal injectables. Coverage from public and private insurers directly impacts patient access to treatment. Favorable reimbursement policies encourage wider adoption of intravitreal injections, while limitations on reimbursement can restrict patient access, especially in cost-sensitive markets.

What are the key challenges in the downstream segment?

Key challenges in the downstream segment include patient non-compliance due to the need for frequent injections, cost-related barriers to access, and variability in reimbursement across regions. Additionally, healthcare providers may face challenges in managing the logistics and ensuring that the injections are administered correctly, which could affect patient outcomes.

How does market competition affect the downstream segment?

Market competition influences the downstream segment by creating a competitive pricing environment, especially as biosimilars and generics enter the market. Competition may also drive innovation in treatment options, such as longer acting injectables, which can lead to better patient compliance and more efficient treatment regimens. However, it also pressures healthcare providers to navigate cost-benefit decisions and treatment choices.

Chapter 1, to describe Intravitreal Injectable product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Intravitreal Injectable, with price, sales, revenue and global market share of Intravitreal Injectable from 2018 to 2023.
Chapter 3, the Intravitreal Injectable competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Intravitreal Injectable breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Drug and disease, with sales market share and growth rate by drug, disease, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Intravitreal Injectable market forecast, by regions, drug and disease, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Intravitreal Injectable.
Chapter 14 and 15, to describe Intravitreal Injectable sales channel, distributors, customers, research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Intravitreal Injectable
   1.2 Market Estimation Caveats and Base Year
   1.3 Market Analysis by Drug
       1.3.1 Overview: Global Intravitreal Injectable Consumption Value by Drug: 2018 Versus 2022 Versus 2029
       1.3.2 Anti-VEGF
       1.3.3 Steroids
       1.3.4 Others
   1.4 Market Analysis by Disease
       1.4.1 Overview: Global Intravitreal Injectable Consumption Value by Disease: 2018 Versus 2022 Versus 2029
       1.4.2 Macular Degeneration
       1.4.3 Macular Edema
       1.4.4 Uveitis
       1.4.5 Retinal Vein Occlusion
       1.4.6 Others
   1.5 Global Intravitreal Injectable Market Size & Forecast
       1.5.1 Global Intravitreal Injectable Consumption Value (2018 & 2022 & 2029)
       1.5.2 Global Intravitreal Injectable Sales Quantity (2018-2029)
       1.5.3 Global Intravitreal Injectable Average Price (2018-2029)

2 Manufacturers Profiles

   2.1 Regeneron Pharmaceuticals (Eylea)
       2.1.1 Regeneron Pharmaceuticals (Eylea) Details
       2.1.2 Regeneron Pharmaceuticals (Eylea) Major Business
       2.1.3 Regeneron Pharmaceuticals (Eylea) Intravitreal Injectable Product and Services
       2.1.4 Regeneron Pharmaceuticals (Eylea) Intravitreal Injectable Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Regeneron Pharmaceuticals (Eylea) Recent Developments/Updates
   2.2 Allergan
       2.2.1 Allergan Details
       2.2.2 Allergan Major Business
       2.2.3 Allergan Intravitreal Injectable Product and Services
       2.2.4 Allergan Intravitreal Injectable Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Allergan Recent Developments/Updates
   2.3 EyePoint Pharmaceuticals
       2.3.1 EyePoint Pharmaceuticals Details
       2.3.2 EyePoint Pharmaceuticals Major Business
       2.3.3 EyePoint Pharmaceuticals Intravitreal Injectable Product and Services
       2.3.4 EyePoint Pharmaceuticals Intravitreal Injectable Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 EyePoint Pharmaceuticals Recent Developments/Updates
   2.4 Genentech
       2.4.1 Genentech Details
       2.4.2 Genentech Major Business
       2.4.3 Genentech Intravitreal Injectable Product and Services
       2.4.4 Genentech Intravitreal Injectable Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Genentech Recent Developments/Updates
   2.5 Kanghong Pharmaceutical
       2.5.1 Kanghong Pharmaceutical Details
       2.5.2 Kanghong Pharmaceutical Major Business
       2.5.3 Kanghong Pharmaceutical Intravitreal Injectable Product and Services
       2.5.4 Kanghong Pharmaceutical Intravitreal Injectable Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Kanghong Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Intravitreal Injectable by Manufacturer

   3.1 Global Intravitreal Injectable Sales Quantity by Manufacturer (2018-2023)
   3.2 Global Intravitreal Injectable Revenue by Manufacturer (2018-2023)
   3.3 Global Intravitreal Injectable Average Price by Manufacturer (2018-2023)
   3.4 Market Share Analysis (2022)
       3.4.1 Producer Shipments of Intravitreal Injectable by Manufacturer Revenue ($MM) and Market Share (%): 2022
       3.4.2 Top 3 Intravitreal Injectable Manufacturer Market Share in 2022
       3.4.2 Top 6 Intravitreal Injectable Manufacturer Market Share in 2022
   3.5 Intravitreal Injectable Market: Overall Company Footprint Analysis
       3.5.1 Intravitreal Injectable Market: Region Footprint
       3.5.2 Intravitreal Injectable Market: Company Product Type Footprint
       3.5.3 Intravitreal Injectable Market: Company Product Application Footprint
   3.6 New Market Entrants and Barriers to Market Entry
   3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

   4.1 Global Intravitreal Injectable Market Size by Region
       4.1.1 Global Intravitreal Injectable Sales Quantity by Region (2018-2029)
       4.1.2 Global Intravitreal Injectable Consumption Value by Region (2018-2029)
       4.1.3 Global Intravitreal Injectable Average Price by Region (2018-2029)
   4.2 North America Intravitreal Injectable Consumption Value (2018-2029)
   4.3 Europe Intravitreal Injectable Consumption Value (2018-2029)
   4.4 Asia-Pacific Intravitreal Injectable Consumption Value (2018-2029)
   4.5 South America Intravitreal Injectable Consumption Value (2018-2029)
   4.6 Middle East and Africa Intravitreal Injectable Consumption Value (2018-2029)

5 Market Segment by Drug

   5.1 Global Intravitreal Injectable Sales Quantity by Drug (2018-2029)
   5.2 Global Intravitreal Injectable Consumption Value by Drug (2018-2029)
   5.3 Global Intravitreal Injectable Average Price by Drug (2018-2029)

6 Market Segment by Disease

   6.1 Global Intravitreal Injectable Sales Quantity by Disease (2018-2029)
   6.2 Global Intravitreal Injectable Consumption Value by Disease (2018-2029)
   6.3 Global Intravitreal Injectable Average Price by Disease (2018-2029)

7 North America

   7.1 North America Intravitreal Injectable Sales Quantity by Drug (2018-2029)
   7.2 North America Intravitreal Injectable Sales Quantity by Disease (2018-2029)
   7.3 North America Intravitreal Injectable Market Size by Country
       7.3.1 North America Intravitreal Injectable Sales Quantity by Country (2018-2029)
       7.3.2 North America Intravitreal Injectable Consumption Value by Country (2018-2029)
       7.3.3 United States Market Size and Forecast (2018-2029)
       7.3.4 Canada Market Size and Forecast (2018-2029)
       7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

   8.1 Europe Intravitreal Injectable Sales Quantity by Drug (2018-2029)
   8.2 Europe Intravitreal Injectable Sales Quantity by Disease (2018-2029)
   8.3 Europe Intravitreal Injectable Market Size by Country
       8.3.1 Europe Intravitreal Injectable Sales Quantity by Country (2018-2029)
       8.3.2 Europe Intravitreal Injectable Consumption Value by Country (2018-2029)
       8.3.3 Germany Market Size and Forecast (2018-2029)
       8.3.4 France Market Size and Forecast (2018-2029)
       8.3.5 United Kingdom Market Size and Forecast (2018-2029)
       8.3.6 Russia Market Size and Forecast (2018-2029)
       8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

   9.1 Asia-Pacific Intravitreal Injectable Sales Quantity by Drug (2018-2029)
   9.2 Asia-Pacific Intravitreal Injectable Sales Quantity by Disease (2018-2029)
   9.3 Asia-Pacific Intravitreal Injectable Market Size by Region
       9.3.1 Asia-Pacific Intravitreal Injectable Sales Quantity by Region (2018-2029)
       9.3.2 Asia-Pacific Intravitreal Injectable Consumption Value by Region (2018-2029)
       9.3.3 China Market Size and Forecast (2018-2029)
       9.3.4 Japan Market Size and Forecast (2018-2029)
       9.3.5 Korea Market Size and Forecast (2018-2029)
       9.3.6 India Market Size and Forecast (2018-2029)
       9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
       9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

   10.1 South America Intravitreal Injectable Sales Quantity by Drug (2018-2029)
   10.2 South America Intravitreal Injectable Sales Quantity by Disease (2018-2029)
   10.3 South America Intravitreal Injectable Market Size by Country
       10.3.1 South America Intravitreal Injectable Sales Quantity by Country (2018-2029)
       10.3.2 South America Intravitreal Injectable Consumption Value by Country (2018-2029)
       10.3.3 Brazil Market Size and Forecast (2018-2029)
       10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

   11.1 Middle East & Africa Intravitreal Injectable Sales Quantity by Drug (2018-2029)
   11.2 Middle East & Africa Intravitreal Injectable Sales Quantity by Disease (2018-2029)
   11.3 Middle East & Africa Intravitreal Injectable Market Size by Country
       11.3.1 Middle East & Africa Intravitreal Injectable Sales Quantity by Country (2018-2029)
       11.3.2 Middle East & Africa Intravitreal Injectable Consumption Value by Country (2018-2029)
       11.3.3 Turkey Market Size and Forecast (2018-2029)
       11.3.4 Egypt Market Size and Forecast (2018-2029)
       11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
       11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

   12.1 Intravitreal Injectable Market Drivers
   12.2 Intravitreal Injectable Market Restraints
   12.3 Intravitreal Injectable Trends Analysis
   12.4 Porters Five Forces Analysis
       12.4.1 Threat of New Entrants
       12.4.2 Bargaining Power of Suppliers
       12.4.3 Bargaining Power of Buyers
       12.4.4 Threat of Substitutes
       12.4.5 Competitive Rivalry
   12.5 Influence of COVID-19 and Russia-Ukraine War
       12.5.1 Influence of COVID-19
       12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

   13.1 Raw Material of Intravitreal Injectable and Key Manufacturers
   13.2 Manufacturing Costs Percentage of Intravitreal Injectable
   13.3 Intravitreal Injectable Production Process
   13.4 Intravitreal Injectable Industrial Chain

14 Shipments by Distribution Channel

   14.1 Sales Channel
       14.1.1 Direct to End-User
       14.1.2 Distributors
   14.2 Intravitreal Injectable Typical Distributors
   14.3 Intravitreal Injectable Typical Customers

15 Research Findings and Conclusion

16 Appendix

   16.1 Methodology
   16.2 Research Process and Data Source
   16.3 Disclaimer

List of Tables

   Table 1. Global Intravitreal Injectable Consumption Value by Drug, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Intravitreal Injectable Consumption Value by Disease, (USD Million), 2018 & 2022 & 2029
   Table 3. Regeneron Pharmaceuticals (Eylea) Basic Information, Manufacturing Base and Competitors
   Table 4. Regeneron Pharmaceuticals (Eylea) Major Business
   Table 5. Regeneron Pharmaceuticals (Eylea) Intravitreal Injectable Product and Services
   Table 6. Regeneron Pharmaceuticals (Eylea) Intravitreal Injectable Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 7. Regeneron Pharmaceuticals (Eylea) Recent Developments/Updates
   Table 8. Allergan Basic Information, Manufacturing Base and Competitors
   Table 9. Allergan Major Business
   Table 10. Allergan Intravitreal Injectable Product and Services
   Table 11. Allergan Intravitreal Injectable Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 12. Allergan Recent Developments/Updates
   Table 13. EyePoint Pharmaceuticals Basic Information, Manufacturing Base and Competitors
   Table 14. EyePoint Pharmaceuticals Major Business
   Table 15. EyePoint Pharmaceuticals Intravitreal Injectable Product and Services
   Table 16. EyePoint Pharmaceuticals Intravitreal Injectable Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 17. EyePoint Pharmaceuticals Recent Developments/Updates
   Table 18. Genentech Basic Information, Manufacturing Base and Competitors
   Table 19. Genentech Major Business
   Table 20. Genentech Intravitreal Injectable Product and Services
   Table 21. Genentech Intravitreal Injectable Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 22. Genentech Recent Developments/Updates
   Table 23. Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
   Table 24. Kanghong Pharmaceutical Major Business
   Table 25. Kanghong Pharmaceutical Intravitreal Injectable Product and Services
   Table 26. Kanghong Pharmaceutical Intravitreal Injectable Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 27. Kanghong Pharmaceutical Recent Developments/Updates
   Table 28. Global Intravitreal Injectable Sales Quantity by Manufacturer (2018-2023) & (K Units)
   Table 29. Global Intravitreal Injectable Revenue by Manufacturer (2018-2023) & (USD Million)
   Table 30. Global Intravitreal Injectable Average Price by Manufacturer (2018-2023) & (US$/Unit)
   Table 31. Market Position of Manufacturers in Intravitreal Injectable, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
   Table 32. Head Office and Intravitreal Injectable Production Site of Key Manufacturer
   Table 33. Intravitreal Injectable Market: Company Product Type Footprint
   Table 34. Intravitreal Injectable Market: Company Product Application Footprint
   Table 35. Intravitreal Injectable New Market Entrants and Barriers to Market Entry
   Table 36. Intravitreal Injectable Mergers, Acquisition, Agreements, and Collaborations
   Table 37. Global Intravitreal Injectable Sales Quantity by Region (2018-2023) & (K Units)
   Table 38. Global Intravitreal Injectable Sales Quantity by Region (2024-2029) & (K Units)
   Table 39. Global Intravitreal Injectable Consumption Value by Region (2018-2023) & (USD Million)
   Table 40. Global Intravitreal Injectable Consumption Value by Region (2024-2029) & (USD Million)
   Table 41. Global Intravitreal Injectable Average Price by Region (2018-2023) & (US$/Unit)
   Table 42. Global Intravitreal Injectable Average Price by Region (2024-2029) & (US$/Unit)
   Table 43. Global Intravitreal Injectable Sales Quantity by Drug (2018-2023) & (K Units)
   Table 44. Global Intravitreal Injectable Sales Quantity by Drug (2024-2029) & (K Units)
   Table 45. Global Intravitreal Injectable Consumption Value by Drug (2018-2023) & (USD Million)
   Table 46. Global Intravitreal Injectable Consumption Value by Drug (2024-2029) & (USD Million)
   Table 47. Global Intravitreal Injectable Average Price by Drug (2018-2023) & (US$/Unit)
   Table 48. Global Intravitreal Injectable Average Price by Drug (2024-2029) & (US$/Unit)
   Table 49. Global Intravitreal Injectable Sales Quantity by Disease (2018-2023) & (K Units)
   Table 50. Global Intravitreal Injectable Sales Quantity by Disease (2024-2029) & (K Units)
   Table 51. Global Intravitreal Injectable Consumption Value by Disease (2018-2023) & (USD Million)
   Table 52. Global Intravitreal Injectable Consumption Value by Disease (2024-2029) & (USD Million)
   Table 53. Global Intravitreal Injectable Average Price by Disease (2018-2023) & (US$/Unit)
   Table 54. Global Intravitreal Injectable Average Price by Disease (2024-2029) & (US$/Unit)
   Table 55. North America Intravitreal Injectable Sales Quantity by Drug (2018-2023) & (K Units)
   Table 56. North America Intravitreal Injectable Sales Quantity by Drug (2024-2029) & (K Units)
   Table 57. North America Intravitreal Injectable Sales Quantity by Disease (2018-2023) & (K Units)
   Table 58. North America Intravitreal Injectable Sales Quantity by Disease (2024-2029) & (K Units)
   Table 59. North America Intravitreal Injectable Sales Quantity by Country (2018-2023) & (K Units)
   Table 60. North America Intravitreal Injectable Sales Quantity by Country (2024-2029) & (K Units)
   Table 61. North America Intravitreal Injectable Consumption Value by Country (2018-2023) & (USD Million)
   Table 62. North America Intravitreal Injectable Consumption Value by Country (2024-2029) & (USD Million)
   Table 63. Europe Intravitreal Injectable Sales Quantity by Drug (2018-2023) & (K Units)
   Table 64. Europe Intravitreal Injectable Sales Quantity by Drug (2024-2029) & (K Units)
   Table 65. Europe Intravitreal Injectable Sales Quantity by Disease (2018-2023) & (K Units)
   Table 66. Europe Intravitreal Injectable Sales Quantity by Disease (2024-2029) & (K Units)
   Table 67. Europe Intravitreal Injectable Sales Quantity by Country (2018-2023) & (K Units)
   Table 68. Europe Intravitreal Injectable Sales Quantity by Country (2024-2029) & (K Units)
   Table 69. Europe Intravitreal Injectable Consumption Value by Country (2018-2023) & (USD Million)
   Table 70. Europe Intravitreal Injectable Consumption Value by Country (2024-2029) & (USD Million)
   Table 71. Asia-Pacific Intravitreal Injectable Sales Quantity by Drug (2018-2023) & (K Units)
   Table 72. Asia-Pacific Intravitreal Injectable Sales Quantity by Drug (2024-2029) & (K Units)
   Table 73. Asia-Pacific Intravitreal Injectable Sales Quantity by Disease (2018-2023) & (K Units)
   Table 74. Asia-Pacific Intravitreal Injectable Sales Quantity by Disease (2024-2029) & (K Units)
   Table 75. Asia-Pacific Intravitreal Injectable Sales Quantity by Region (2018-2023) & (K Units)
   Table 76. Asia-Pacific Intravitreal Injectable Sales Quantity by Region (2024-2029) & (K Units)
   Table 77. Asia-Pacific Intravitreal Injectable Consumption Value by Region (2018-2023) & (USD Million)
   Table 78. Asia-Pacific Intravitreal Injectable Consumption Value by Region (2024-2029) & (USD Million)
   Table 79. South America Intravitreal Injectable Sales Quantity by Drug (2018-2023) & (K Units)
   Table 80. South America Intravitreal Injectable Sales Quantity by Drug (2024-2029) & (K Units)
   Table 81. South America Intravitreal Injectable Sales Quantity by Disease (2018-2023) & (K Units)
   Table 82. South America Intravitreal Injectable Sales Quantity by Disease (2024-2029) & (K Units)
   Table 83. South America Intravitreal Injectable Sales Quantity by Country (2018-2023) & (K Units)
   Table 84. South America Intravitreal Injectable Sales Quantity by Country (2024-2029) & (K Units)
   Table 85. South America Intravitreal Injectable Consumption Value by Country (2018-2023) & (USD Million)
   Table 86. South America Intravitreal Injectable Consumption Value by Country (2024-2029) & (USD Million)
   Table 87. Middle East & Africa Intravitreal Injectable Sales Quantity by Drug (2018-2023) & (K Units)
   Table 88. Middle East & Africa Intravitreal Injectable Sales Quantity by Drug (2024-2029) & (K Units)
   Table 89. Middle East & Africa Intravitreal Injectable Sales Quantity by Disease (2018-2023) & (K Units)
   Table 90. Middle East & Africa Intravitreal Injectable Sales Quantity by Disease (2024-2029) & (K Units)
   Table 91. Middle East & Africa Intravitreal Injectable Sales Quantity by Region (2018-2023) & (K Units)
   Table 92. Middle East & Africa Intravitreal Injectable Sales Quantity by Region (2024-2029) & (K Units)
   Table 93. Middle East & Africa Intravitreal Injectable Consumption Value by Region (2018-2023) & (USD Million)
   Table 94. Middle East & Africa Intravitreal Injectable Consumption Value by Region (2024-2029) & (USD Million)
   Table 95. Intravitreal Injectable Raw Material
   Table 96. Key Manufacturers of Intravitreal Injectable Raw Materials
   Table 97. Intravitreal Injectable Typical Distributors
   Table 98. Intravitreal Injectable Typical Customers

List of Figures

   Figure 1. Intravitreal Injectable Picture
   Figure 2. Global Intravitreal Injectable Consumption Value by Drug, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Intravitreal Injectable Consumption Value Market Share by Drug in 2022
   Figure 4. Anti-VEGF Examples
   Figure 5. Steroids Examples
   Figure 6. Others Examples
   Figure 7. Global Intravitreal Injectable Consumption Value by Disease, (USD Million), 2018 & 2022 & 2029
   Figure 8. Global Intravitreal Injectable Consumption Value Market Share by Disease in 2022
   Figure 9. Macular Degeneration Examples
   Figure 10. Macular Edema Examples
   Figure 11. Uveitis Examples
   Figure 12. Retinal Vein Occlusion Examples
   Figure 13. Others Examples
   Figure 14. Global Intravitreal Injectable Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 15. Global Intravitreal Injectable Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 16. Global Intravitreal Injectable Sales Quantity (2018-2029) & (K Units)
   Figure 17. Global Intravitreal Injectable Average Price (2018-2029) & (US$/Unit)
   Figure 18. Global Intravitreal Injectable Sales Quantity Market Share by Manufacturer in 2022
   Figure 19. Global Intravitreal Injectable Consumption Value Market Share by Manufacturer in 2022
   Figure 20. Producer Shipments of Intravitreal Injectable by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
   Figure 21. Top 3 Intravitreal Injectable Manufacturer (Consumption Value) Market Share in 2022
   Figure 22. Top 6 Intravitreal Injectable Manufacturer (Consumption Value) Market Share in 2022
   Figure 23. Global Intravitreal Injectable Sales Quantity Market Share by Region (2018-2029)
   Figure 24. Global Intravitreal Injectable Consumption Value Market Share by Region (2018-2029)
   Figure 25. North America Intravitreal Injectable Consumption Value (2018-2029) & (USD Million)
   Figure 26. Europe Intravitreal Injectable Consumption Value (2018-2029) & (USD Million)
   Figure 27. Asia-Pacific Intravitreal Injectable Consumption Value (2018-2029) & (USD Million)
   Figure 28. South America Intravitreal Injectable Consumption Value (2018-2029) & (USD Million)
   Figure 29. Middle East & Africa Intravitreal Injectable Consumption Value (2018-2029) & (USD Million)
   Figure 30. Global Intravitreal Injectable Sales Quantity Market Share by Drug (2018-2029)
   Figure 31. Global Intravitreal Injectable Consumption Value Market Share by Drug (2018-2029)
   Figure 32. Global Intravitreal Injectable Average Price by Drug (2018-2029) & (US$/Unit)
   Figure 33. Global Intravitreal Injectable Sales Quantity Market Share by Disease (2018-2029)
   Figure 34. Global Intravitreal Injectable Consumption Value Market Share by Disease (2018-2029)
   Figure 35. Global Intravitreal Injectable Average Price by Disease (2018-2029) & (US$/Unit)
   Figure 36. North America Intravitreal Injectable Sales Quantity Market Share by Drug (2018-2029)
   Figure 37. North America Intravitreal Injectable Sales Quantity Market Share by Disease (2018-2029)
   Figure 38. North America Intravitreal Injectable Sales Quantity Market Share by Country (2018-2029)
   Figure 39. North America Intravitreal Injectable Consumption Value Market Share by Country (2018-2029)
   Figure 40. United States Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 41. Canada Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 42. Mexico Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 43. Europe Intravitreal Injectable Sales Quantity Market Share by Drug (2018-2029)
   Figure 44. Europe Intravitreal Injectable Sales Quantity Market Share by Disease (2018-2029)
   Figure 45. Europe Intravitreal Injectable Sales Quantity Market Share by Country (2018-2029)
   Figure 46. Europe Intravitreal Injectable Consumption Value Market Share by Country (2018-2029)
   Figure 47. Germany Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 48. France Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 49. United Kingdom Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 50. Russia Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 51. Italy Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 52. Asia-Pacific Intravitreal Injectable Sales Quantity Market Share by Drug (2018-2029)
   Figure 53. Asia-Pacific Intravitreal Injectable Sales Quantity Market Share by Disease (2018-2029)
   Figure 54. Asia-Pacific Intravitreal Injectable Sales Quantity Market Share by Region (2018-2029)
   Figure 55. Asia-Pacific Intravitreal Injectable Consumption Value Market Share by Region (2018-2029)
   Figure 56. China Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 57. Japan Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 58. Korea Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 59. India Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 60. Southeast Asia Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 61. Australia Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 62. South America Intravitreal Injectable Sales Quantity Market Share by Drug (2018-2029)
   Figure 63. South America Intravitreal Injectable Sales Quantity Market Share by Disease (2018-2029)
   Figure 64. South America Intravitreal Injectable Sales Quantity Market Share by Country (2018-2029)
   Figure 65. South America Intravitreal Injectable Consumption Value Market Share by Country (2018-2029)
   Figure 66. Brazil Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 67. Argentina Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 68. Middle East & Africa Intravitreal Injectable Sales Quantity Market Share by Drug (2018-2029)
   Figure 69. Middle East & Africa Intravitreal Injectable Sales Quantity Market Share by Disease (2018-2029)
   Figure 70. Middle East & Africa Intravitreal Injectable Sales Quantity Market Share by Region (2018-2029)
   Figure 71. Middle East & Africa Intravitreal Injectable Consumption Value Market Share by Region (2018-2029)
   Figure 72. Turkey Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 73. Egypt Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 74. Saudi Arabia Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 75. South Africa Intravitreal Injectable Consumption Value and Growth Rate (2018-2029) & (USD Million)
   Figure 76. Intravitreal Injectable Market Drivers
   Figure 77. Intravitreal Injectable Market Restraints
   Figure 78. Intravitreal Injectable Market Trends
   Figure 79. Porters Five Forces Analysis
   Figure 80. Manufacturing Cost Structure Analysis of Intravitreal Injectable in 2022
   Figure 81. Manufacturing Process Analysis of Intravitreal Injectable
   Figure 82. Intravitreal Injectable Industrial Chain
   Figure 83. Sales Quantity Channel: Direct to End-User vs Distributors
   Figure 84. Direct Channel Pros & Cons
   Figure 85. Indirect Channel Pros & Cons
   Figure 86. Methodology
   Figure 87. Research Process and Data Source